The landscape of clinical research is undergoing a profound transformation. As the costs of traditional human trials soar and recruitment challenges mount, a new frontier is emerging: Synthetic Data. Often referred to as in silico evidence, this technology uses advanced computational models to generate data that mimics the statistical properties of real-world patients without requiring their physical presence in a trial.

While it may sound like science fiction, the FDA is increasingly engaging with synthetic data as a legitimate tool to supplement clinical evidence, particularly in the fields of medical devices and rare diseases.

What Exactly is Synthetic Data?

Synthetic data is not “fake” data; it is mathematically generated data based on real-world datasets. By using machine learning and historical clinical trial results, researchers can create a “Digital Twin” of a patient. These digital subjects can then be used in several ways:

• Augmenting Control Arms: Reducing the number of patients needed for a placebo group by using a “Synthetic Control Arm.”
• Simulating Outcomes: Predicting how a drug or device might behave in populations that are difficult to recruit, such as pediatric or pregnant patients.
• Sensitivity Analysis: Stress-testing a trial design before the first human subject is ever enrolled.

The FDA’s Current Regulatory Stance

The FDA is cautious but optimistic. Through initiatives like the MDIC (Medical Device Innovation Consortium) and various pilot programs, the agency has signaled that in silico evidence can be used to support regulatory submissions—if the models are properly validated.

However, “Validation” is the high hurdle every sponsor must clear. The FDA requires proof that the computational model is a “credible” representation of biological reality. This involves rigorous verification (is the math correct?) and validation (does the model match real human data?).

Key Benefits for Clinical Strategy

Integrating synthetic data into your development pipeline offers three strategic advantages:

1. Accelerating Market Entry By reducing the size of required control groups, synthetic data can shave months—or even years—off the clinical development timeline. This is a game-changer for orphan drugs where the total patient population is extremely small.
2. Enhancing Patient Ethics In trials for life-threatening conditions, assigning a patient to a placebo group can be ethically challenging. Synthetic Control Arms allow more (or all) real-world participants to receive the active treatment while still maintaining a statistically valid comparison.
3. Cost Mitigation Traditional trials are the most expensive part of drug development. Synthetic data reduces the logistical burden of site management, monitoring, and patient stipends, allowing for a more lean and efficient research model.

The Challenges: Data Integrity and Bias

The “Garbage In, Garbage Out” rule applies heavily here. If the underlying real-world data used to train the AI is biased or incomplete, the synthetic data will be as well. Ensuring Data Integrity and transparency in the algorithms is paramount to gaining FDA approval. Sponsors must be prepared to defend their “Black Box” models during a regulatory audit.

Are You Ready for the In Silico Future?

Synthetic data is moving from the experimental phase to the regulatory mainstream. As we move into 2026, understanding how to leverage in silico evidence will be a defining factor for leaders in the pharmaceutical and med-tech industries.

How do you choose the right historical data to build a synthetic arm? What are the specific validation protocols the FDA looks for in a 510(k) or PMA submission?

Master the Science of Synthetic Evidence

To help you navigate this complex and high-reward field, we are hosting a forward-looking webinar: “Synthetic Data in Clinical Trials: FDA’s Current Stance on In Silico Evidence.”

We will dive into the technical requirements for model validation, the ethical implications of digital twins, and the most recent case studies where synthetic data successfully supported an FDA approval.

Register for the Webinar: Synthetic Data and In Silico Evidence